TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today positive results from its Phase IIb randomized, double blind, placebo controlled non-inferiority trial of its prescription topical analgesic EpiCeptTM NP-1 Cream in post-herpetic neuralgia (PHN). The trial met its primary endpoints and demonstrated a favorable safety profile compared with gabapentin.
